Food and Drug Administration, Dockets Management Branch, 5630 Fishers Lane - Room 1061- HFA-305, Rockville, MD, 20852; 301-827-6860; Fax 301-827-6870; TTY/TDD Users 1-800-735-2258 - [E-mail Us]

DOCKETS ENTERED on October 28, 2002

TABLE OF CONTENTS

Hyper links are part of the Docket  title - not all dockets/documents are linked

NOTE:  Documents received by the Dockets Management Branch "MAY" be posted on the Internet. PLEASE DO NOT include personal identifying information, i.e. date of birth, social security number, etc., in your correspondence.

[FDA DOCKETS PAGE] [FDA HOME PAGE]  [ ITEM CODES ]

 
00P-1211 Establish Mandatory Pre-Market Safety Testing for GE Foods *
02D-0254 Inhalation Drug Products packaged in Semipermeable container *
02N-0241 Aluminum in Large & Small Volume Parenterals *
02N-0445 FDA Regulation of Combination Products; Public Hearing *
02N-0471 Cox-2 Inhibitors: Vioxx and Celebrex *
02P-0135 Orally-Administered Levothyroxine Sodium all NDAs & ANDAs *
02P-0431 Delcobese Tablets and Capsules *
02P-0469 NANDA for Brimonidine Tartrate Ophthalmic Solution 0.2% *
02P-0470 Change Dosgae Form of Eqvalan Paste 1.87% From Paste to Gran *

00P-1211 Establish Mandatory Pre-Market Safety Testing for GE Foods

LET 3 The Center for Food Safety Vol#: 785

00V-1377 Laser Light Show(2) LM-10 Micro Yag Projection systems

EXP 1 Mighty Ducks Hocky Club, Inc. Vol#: 1

01N-0067 Reclassification of Dental Mercury

SUP 3 Leslie Joy Smith Vol#: 15

02D-0254 Inhalation Drug Products packaged in Semipermeable container

C 4 Aventis Phamaceuticals, Inc. Vol#: 1

02N-0241 Aluminum in Large & Small Volume Parenterals

C 1 AdvaMed Vol#: 1

02N-0417 Applications for FDA Approval to Market a New Drug

BKG 1 Background Material Vol#: 1

NPR 1 Vol#: 1

02N-0445 FDA Regulation of Combination Products; Public Hearing

APE 1 Pharmacia Corporation Vol#: 2

APE 2 Food and Drug Law Institute Vol#: 2

APE 3 Biotechnology Industry Organization Vol#: 2

APE 4 Molnlycke Health Care, Inc. Vol#: 2

APE 5 Boehringer Ingelheim Pharmaceuticals Inc Vol#: 2

NHC 1 Vol#: 1

02N-0471 Cox-2 Inhibitors: Vioxx and Celebrex

CO 1 Boies, Schiller & Flexner, LLP Vol#: 1

02P-0135 Orally-Administered Levothyroxine Sodium all NDAs & ANDAs

M 4 HFD-820 Vol#: 1

02P-0431 Delcobese Tablets and Capsules

LET 1 Sonnenschein, Nath & Rosenthal Vol#: 1

02P-0469 NANDA for Brimonidine Tartrate Ophthalmic Solution 0.2%

ACK 1 HFA-305 Vol#: 1

CP 1 Allergan, Inc. Vol#: 1

02P-0470 Change Dosgae Form of Eqvalan Paste 1.87% From Paste to Gran

ACK 1 HFA-305 Vol#: 1

CP 1 Karen A. Sisson Vol#: 1